Clinical trial ADRIATIC
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC)
Cancers | |
---|---|
Organ | Lung |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | AstraZeneca |
EudraCT Identifier | 2018-000867-10 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03703297 |
Inclusion criteria | 4 lines chemotherapy and radiation |
Last update |